United States: Major Mental Illness, Substance Use Disorder Reforms, Opioid Abuse Treatment Funding Included In 21st Century Cures Act

Advocates have been pushing hard over the past couple of years for the reform and expansion of mental illness and substance use disorder (i.e., behavioral health) treatment in the U.S. The 21st Century Cures Act — which has cleared Congress and is awaiting the President's signature — includes a number of important provisions that reflect those efforts, including sections intended to strengthen, promote, and expand access to information, care, and coverage with respect to behavioral health care across communities and for individuals, families, and the nation's health care workforce. The Act also includes $1 billion in block grant funding to target the "epidemic of death" associated with the opioid abuse crisis.

Mental Health and Substance Abuse Disorder Provisions

In one of the most noteworthy behavioral health provisions, the Act strengthens leadership within the Substance Abuse and Mental Health Services Administration (SAMHSA) by creating a new Assistant Secretary position. The new role will oversee mental health and substance abuse research, funding, and evidence-based health care practices, and will drive and coordinate federal policy in this area. To do so, the Assistant Secretary will consult with stakeholders to improve community-based and other mental health services, including care for adults and children with serious mental illness, as well as collaborate with other federal departments, including the Departments of Defense, Veterans Affairs, Housing and Urban Development, and Labor, to improve care for veterans and service members and support programs to address chronic homelessness. The Assistant Secretary is also tasked with working with stakeholders to improve the recruitment and retention of mental health and substance use disorder professionals.

The Act also addresses Medicaid coverage of mental health services through various pathways. One section, for instance, provides that effective January 1, 2019, children receiving Medicaid-covered inpatient psychiatric hospital services will also be eligible for the full range of early and periodic screening, diagnostic, and treatment services. Another section clarifies that Medicaid is permitted to pay providers for the delivery of both mental health and primary-care services to the same patient on the same day, which had been an ongoing point of confusion for many providers. The Act also directs the Secretary to report on certain data related to Medicaid managed care regulations and separately report on states that have participated in the Medicaid Emergency Psychiatric Demonstration Project established by the Affordable Care Act.

With regard to promoting and expanding access to substance use disorder care, the Act targets helping individuals and families, as well as affected children and adolescents. Specifically, the Act promotes integration of primary and behavioral health care, strengthens community crisis response systems, and supports mental health and substance use disorder services on college campuses. The Act also increases access to pediatric mental health care and early intervention services by authorizing and reauthorizing important programs for children, including those at risk of or already suffering from mental health or substance use disorders.

Additionally, the Act seeks to improve enforcement of rules for insurers to cover behavioral health care on parity with physical health. It requires the Department of Health and Human Services (HHS) to seek public comment within six months of the Act's enactment so as to produce an action plan for improved federal and state coordination related to the enforcement of mental health parity and addiction equity requirements. The Act also requires the Administrator of the Centers for Medicare & Medicaid Services to issue an annual report for five years that summarizes the results of all closed federal investigations completed during the preceding year with findings of any serious violation regarding compliance with existing behavioral health parity requirements. Furthermore, the Act requires HHS to issue new guidance documents to assist health plan compliance with existing mental health parity requirements, including disclosure requirements and non-quantitative treatment limitations.

The Act addresses numerous other significant behavioral health issues, including: (i) requiring HHS/Office of Civil Rights to clarify when providers can use patient information protected by HIPAA for treatment purposes and share such information with patients' family members and caregivers; (ii) boosting financial support to train mental health professionals; and (iii) important justice system reforms, including creating a Drug and Mental Health Court pilot program similar to problem-solving court programs many state and local governments already operate.

Opioid Abuse Treatment Block Grants

Overdose deaths associated with prescription and illicit opioids increased to 33,091 in 2015, according to Centers for Disease Control and Prevention (CDC) data. The increase in the number of deaths was driven, in large part, by a sharp increase in deaths related to heroin and synthetic opioid use. Heroin overdose deaths accounted for 12,990 of the deaths in 2015 – a 23 percent increase over deaths due to heroin overdoses in 2014.

Overdose deaths involving synthetic opioids, other than methadone, accounted for 9,580 of the deaths – a 73 percent increase over 2014. The synthetic opioid fentanyl involved in these deaths appears to have been illicitly manufactured. Taken together, 19,885 deaths in America in 2015 involved primarily illicit opioids: heroin, synthetic opioids other than methadone, or a mixture of the two. At the same time, overdose deaths involving prescription opioids rose only slightly.

In Section 1003 of the Cures Act, Congress attempts to address what Dr. Thomas Frieden, the Director of the CDC, describes as the worsening "epidemic of deaths" by appropriating $1 billion for use by the state governments to deal with the "opioid abuse crisis." The appropriation covers a two-year period ($500 million for fiscal years 2017 and 2018, respectively). These funds will be made available in the form of block grants by the HHS Secretary. In awarding such grants, the Secretary is to give preference to states with an incidence of opioid use disorders that is substantially higher relative to other states.

The block grants awarded to state governments are to be used for carrying out activities that supplement programs already undertaken by state agencies responsible for administering the substance abuse prevention and treatment block grants under subpart II of part B of title XIX of the Public Health Service Act (42 U.S.C. 300x–21 et seq.). The Act identifies some of the activities for which the grant money may be used. These activities include: i) improving state prescription drug monitoring programs; ii) implementing prevention activities and evaluating such activities to identify effective strategies to prevent opioid abuse; iii) training health care practitioners where such training would include best practices for prescribing opioids, pain management, recognizing potential cases of substance abuse, referral of patients to treatment programs, and overdose prevention; and iv) supporting access to health care services, including those services provided by federally certified opioid treatment programs or other appropriate health care providers to treat substance use disorders. In addition to the foregoing, the money may be used for other public health-related activities "as the state determines appropriate" to address opioid abuse within the state.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.